Dementia Discovery Fund, backed by more than half a dozen corporates, reached its final close after AARP supplied $60m.
Dementia Discovery Fund (DDF), a strategic investment fund backed by pharmaceutical firms Biogen, GlaxoSmithKline (GSK), Johnson & Johnson, Eli Lilly, Otsuka, Pfizer and Takeda, reached a $350m final close on Monday.
The completion of the fund came through a $60m commitment from senior citizen’s lobbying group AARP.
DDF also identified care provider UnitedHealth, insurance supplier Aegon, diagnostic testing services firm Quest Diagnostics and the UK government-owned British Patient Capital as new backers.
In addition to the corporates, the fund’s limited…
